Compare TME & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TME | VTRS |
|---|---|---|
| Founded | N/A | 1961 |
| Country | China | United States |
| Employees | N/A | 30000 |
| Industry | Broadcasting | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 18.7B |
| IPO Year | 2018 | 2019 |
| Metric | TME | VTRS |
|---|---|---|
| Price | $8.81 | $16.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $19.44 | $13.50 |
| AVG Volume (30 Days) | 8.0M | ★ 10.3M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | 2.66% | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $10.73 | $4.41 |
| Revenue Next Year | $10.19 | $1.96 |
| P/E Ratio | ★ $15.69 | $320.90 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.94 | $9.43 |
| 52 Week High | $26.70 | $18.39 |
| Indicator | TME | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 40.73 |
| Support Level | $8.69 | $15.82 |
| Resistance Level | $9.78 | $16.54 |
| Average True Range (ATR) | 0.33 | 0.52 |
| MACD | -0.11 | -0.20 |
| Stochastic Oscillator | 33.24 | 12.95 |
Tencent Music is the largest online music streaming platform in China, established in 2016 through the merger of QQ Music, Kuwo Music, and Kugou Music. Tencent, its largest shareholder, holds over 50% of the shares and more than 90% of the voting rights. Beyond streaming services, Tencent Music generates revenue through a diverse range of offerings, including podcasts, livestreaming, concerts, and karaoke.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.